MondayNightIBD | Lymphoma Risks in IBD #Back2Basics | February 27, 2023 | Joseph Sleiman, MD*Pre-assessment* Survey

Before you participate in this activity, please take this pre-assessment. Taking this pre-assessment does not immediately qualify learners to earn credit.

Certificates of credit will only be sent to learners who also receive a passing score on the post-test (separate from this survey), and fill out the evaluation form and application for credit.

2.Which population could benefit from testing for EBV serology before starting thiopurines?(Required.)

Women < age 35

Men < age 35

Women > age 50

Men > age 50

3.You are starting a 22 year-old male with severe Crohn’s ileitis on IFX and you recommend combination therapy with thiopurine to prevent anti-drug antibodies formation. He is concerned about the increased risk of lymphoma with combination therapy.
What information do you share with him about the risk of lymphoma with AZA/6MP to reach a shared decision? (Required.)

He is not at increased risk because of his age

Risk increased only if he is EBV +

Risk increase after 1-2 years of AZA/6MP use

Risk persists after cessation of AZA/6MP

4.Please let us know who you are so we can connect your responses to your post-test & application to claim CME credit (completed after participating in the activity)

First & Last Name

State/Province

ZIP/Postal Code

Country

Email Address